Conventional ultrasound and contrast-enhanced ultrasound radiomics in breast cancer and molecular subtype diagnosis
Frontiers in Oncology · 23.05.2023 · 13
DOI: 10.3389/fonc.2023.1158736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 23.05.2023. Verfasst von Xuantong Gong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences an…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to explore the value of conventional ultrasound (CUS) and contrast-enhanced ultrasound (CEUS) radiomics to diagnose breast cancer and predict its molecular subtype.
Method
A total of 170 lesions (121 malignant, 49 benign) were selected from March 2019 to January 2022. Malignant lesions were further divided into six categories of molecular subtype: (non-)Luminal A, (non-)Luminal B, (non-)human epidermal growth factor receptor 2 (HER2) overexpression, (non-)triple-negative breast cancer (TNBC), hormone receptor (HR) positivity/negativity, and HER2 positivity/negativity. Participants were examined using CUS and CEUS before surgery. Regions of interest images were manually segmented. The pyradiomics toolkit and the maximum relevance minimum redundancy algorithm were utilized to extract and select features, multivariate logistic regression models of CUS, CEUS, and CUS combined with CEUS radiomics were then constructed and evaluated by fivefold cross-validation.
Results
The accuracy of the CUS combined with CEUS model was superior to CUS model (85.4% vs. 81.3%, p<0.01). The accuracy of the CUS radiomics model in predicting the six categories of breast cancer is 68.2% (82/120), 69.3% (83/120), 83.7% (100/120), 86.7% (104/120), 73.5% (88/120), and 70.8% (85/120), respectively. In predicting breast cancer of Luminal A, HER2 overexpression, HR-positivity, and HER2 positivity, CEUS video improved the predictive performance of CUS radiomics model [accuracy=70.2% (84/120), 84.0% (101/120), 74.5% (89/120), and 72.5% (87/120), p<0.01].
Conclusion
CUS radiomics has the potential to diagnose breast cancer and predict its molecular subtype. Moreover, CEUS video has auxiliary predictive value for CUS radiomics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- School of Computer Science and Engineering, Beihang University, Beijing, China.
- Department of Ultrasound, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
- Hangzhou Innovation Institute, Beihang University, Hangzhou, China.
- State Key Laboratory of Virtual Reality Technology and Systems, School of Computer Science and Engineering, Beijing Advanced Innovation Center for Big Data and Brain Computing (BDBC), Beihang University, Beijing, China.
- Department of Ultrasound, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zitieren
APA
Gong, X., Li, Q., Gu, L., Chen, C., Liu, X., Zhang, X., Wang, B., Sun, C., Yang, D., Li, L., & Wang, Y. (2023). Conventional ultrasound and contrast-enhanced ultrasound radiomics in breast cancer and molecular subtype diagnosis. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1158736
Vancouver
Gong X, Li Q, Gu L, Chen C, Liu X, Zhang X, et al. Conventional ultrasound and contrast-enhanced ultrasound radiomics in breast cancer and molecular subtype diagnosis. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1158736
BibTeX
@article{Gong2023,
author = {Gong, Xuantong and Li, Qingfeng and Gu, Lishuang and Chen, Chen and Liu, Xuefeng and Zhang, Xuan and Wang, Bo and Sun, Chao and Yang, Di and Li, Lin and Wang, Yong},
title = {Conventional ultrasound and contrast-enhanced ultrasound radiomics in breast cancer and molecular subtype diagnosis},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1158736}
}
EUVIMED